BIOMARKERS & IMMUNO-ONCOLOGY WORLD CONGRESS 2017
The Leading Annual Meeting Where Big Pharma and Biotech Drive Innovation and
Collaboration in Biomarkers, Diagnostics and Immunotherapy
Cambridge Healthtech Institute's Biomarker Series signature event, the 13th Annual Biomarkers & Immuno-Oncology World Congress, was recently held May 2 – 4, in Philadelphia, PA.
This year’s event featured more than 350 participants, from 21 different countries and more than 220 different organizations (including 22% from Pharma). The congress offered a balance of scientific sessions and ample networking opportunities. More
than 70% of the participants were decision makers. The latest research and strategic presentations and brainstorming sessions were featured at this year’s event. The Biomarker & Immuno-Oncology World Congress once again delivered, with more
than 100 presentations, and a sold-out exhibit hall.
SHORT COURSES*
MONDAY AFTERNOON, MAY 1 | 1:00 – 4:00 PM
SC1: FIT-FOR-PURPOSE BIOMARKER ASSAY DEVELOPMENT AND VALIDATION
MONDAY EVENING, MAY 1 | 5:00 – 8:00 PM
Dinner Workshop
SC2: LIQUID BIOPSY FOR IMMUNO-ONCOLOGY AND PRECISION MEDICINE
Dinner Short Course
SC3: PREPARING FOR COMPANION DIAGNOSTIC DEVICE STUDIES AND SUBMISSIONS TO FDA
TUESDAY EVENING, MAY 2 | 6:00 – 9:00 PM
Dinner Short Course
SC4: NEXT-GENERATION SEQUENCING AS A CLINICAL TEST
Dinner ThinkTank
SC5: PD-L1 ASSAYS FOR BIOMARKERS AND COMPANION DIAGNOSTICS
WEDNESDAY EVENING, MAY 3 | 6:15 – 9:15 PM
Dinner Executive ThinkTank
SC6: COMPLEMENTARY DIAGNOSTICS
Dinner Short Course
SC7: IMMUNE MONITORING IN CANCER
Here is what some people had to say about this year’s event.
“What’s making immuno-oncology so exciting is the durable response that we are seeing in a subset of patients. The Biomarkers and Immuno-Oncology World Congress brings together a diverse mix of industry experts to discuss the new and exciting
data that is beginning to emerge around next-generation immuno-diagnostics.”
Colton B., Manager, Business Development at Biodesix
"We see novel epigenetic biomarkers becoming a powerful success-enabler of new immuno and combo therapies, so for us, the knowledge exchanged at the 2017 conference was incredibly valuable and established a great foundation for future meetings. Very much
looking forward to 2018"
Jeb C., Chairman, CEO and Co-Founder, Genome Profiling (GenPro)
“truly a state-of-the-start assembly of speakers and subjects on immunotherapy; provides a diverse perspective of the immunotherapy landscape”
Susan S., Medical Oncologist, Memorial Sloan Kettering Cancer Ctr.
“As a Clinical Trial Biomarker RD leader, I had great experience to participate the face-to-face sharing and discussing the key practical but challenging issues of immune oncology biomarkers such as PD-L1 in clinical trial, from analytical to clinical
validation, as well as regulatory advisory comments”.
Bin Y., Exec Dir Biology & Clinical Biomarker, Shenogen Pharma Grp